Evidence of a pharmacogenomic response to interleukin-1 receptor antagonist in rheumatoid arthritis

Genes and Immunity

Volumn 6, Issue 6, 2005, Pages 467-471

  Camp, N J ^a,c   Cox, A ^a,d   di Giovine, F S ^a   McCabe, D ^b   Rich, W ^b   Duff, G W ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b AMGEN INC   (United States)

^c UNIVERSITY OF SHEFFIELD   (United Kingdom)

^d UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

IL 1ra; Pharmacogenomics; Rheumatoid arthritis; SNP

Indexed keywords

INTERLEUKIN 1; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; PLACEBO; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; IL1RN PROTEIN, HUMAN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RECOMBINANT PROTEIN; SIALOGLYCOPROTEIN;

ALLELE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; GENOTYPE; HETEROZYGOTE; HUMAN; JOINT SWELLING; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PHARMACOGENOMICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; STATISTICAL SIGNIFICANCE; DOUBLE BLIND PROCEDURE; DRUG RESISTANCE; GENETICS; SINGLE NUCLEOTIDE POLYMORPHISM;

ALLELES; ARTHRITIS, RHEUMATOID; DOUBLE-BLIND METHOD; DRUG RESISTANCE; GENOTYPE; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1; POLYMORPHISM, SINGLE NUCLEOTIDE; RECOMBINANT PROTEINS; SIALOGLYCOPROTEINS;

EID: 26944461272     PISSN: 14664879     EISSN: 14765470     Source Type: Journal    
DOI: 10.1038/sj.gene.6364228     Document Type: Article

References (29)

1. Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 2001; 22: 907-916.
2. di Giovine FS, Nuki G, Duff GW. Tumour necrosis factor in synovial exudates. Ann Rheum Dis 1988; 47: 768-772.
3. Eastgate JA, Symons JA, Wood NC, Grinlinton FM, di Giovine FS, Duff GW. Correlation of plasma interleukin-1 levels with disease activity in rheumatoid arthritis. Lancet 1988; 8613: 706-709.
4. Brennan F, Jackson A, Chantry D, Maini R, Feldmann M. Inhibitory effect of TNF-alpha antibodies on synovial cell interleukin-1 production in rheumatoid-arthritis. Lancet 1989; 8657: 244-247.
5. Dinarello CA. Biologic basis for interleukin-1 in disease. Blood 1996; 87: 2095-2147.
6. Horai R, Saijo S, Tanioka H et al. Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin-1 receptor antagonist-deficient mice. J Exp Med 2000; 191: 313-320.
7. Joosten LA, Helsen MMA, van de Loo FAJ, van den Berg WB. Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice. A comparative study using anti-TNFα, anti-IL-1α/β, and IL-1ra. Arthr Rheum 1996; 39: 797-809.
8. Bendele A, McAbee T, Sennello G, Frazier J, Chlipala E, McCabe D. Efficacy of sustained blood levels of interleukin-1 receptor antagonist in animal models of arthritis. Arth Rheum 1999; 42: 498-506.
9. Bresnihan B, Alvaro-Gracia JM, Cobby M et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthr Rheum 1998; 41: 2196-2204.
10. Nicklin MJH, Weith A, Duff GW. A physical map of the region encompassing the human interleukin-1 alpha, beta and the interleukin-1 receptor antagonist genes. Genomics 1994; 19: 382-384.
11. Nothwang HG, Strahm B, Denich D et al. Molecular cloning of the interleukin-1 gene cluster: Construction of an integrated YAC/PAC contig and partial transcriptional map in the region of chromosome 2q13. Genomics 1997; 41: 370-378.
12. Cox A, Camp NJ, Nicklin MJH, di Giovine FS, Duff GW. An analysis of linkage disequilibrium in the interleukin-1 gene cluster, using a novel grouping method for multiallelic markers. Am J Hum Genet 1998; 62: 1180-1188.
13. Pociot F, Molvig J, Wogensen L, Worsae H, Nerup J. A TaqI polymorphism in the human interleukin-1 beta (IL-1beta) gene correlates with IL-1 beta secretion in vitro. Eur J Clin Invest 1992; 22: 396-402.
14. Cox A, Camp NJ, Cannings C et al. Combined sib-TDT and TDT provide evidence for linkage of the interleukin-1 gene cluster to erosive rheumatoid arthritis. Hum Mol Genet 1999; 8: 1707-1713.
15. Cantagrel A, Navaux F, Loubet-Lescoulie P et al. Interleukin-1β, interleukin-1 receptor antagonist, interleukin-4, and interleukin-10 gene polymorphisms. Relationship to occurrence and severity of rheumatoid arthritis. Arthr Rheum 1999; 42: 1093-1100.
16. Jouvenne P, Chaudhary A, Buchs N, di Giovine FS, Duff GW, Miossec P. Possible genetic association between interleukin-1 alpha gene polymorphism and the severity of chronic polyarthritis. Eur Cytokine Network 1999; 10: 33-36.
17. Elliott M, Maini R, Feldmann M et al. Treatment of rheumatoid-arthritis with chimeric monoclonal-antibodies to tumor-necrosis-factor-alpha. Arthr Rheum 1993; 36: 1681-1690.
18. Nicoll JA, Mrak RE, Graham DI et al. Association of interleukin-1 gene polymorphisms with Alzheimer's diseased. Ann Neurol 2000; 47: 365-368.
19. Kornman KS, Crane A, Wang H-Y et al. The interleukin-1 genotype as a severity factor in adult periodontal disease. J Clin Periodontol 1997; 24: 72-77.
20. Hulkkonen J, Laippala P, Hurme M. A rare allele combination of the interleukin-1 gene complex is associated with high interleukin-1 beta plasma levels in healthy individuals. Eur Cytokine Network 2000; 11: 251-255.
21. Hernandez-Guerrero C, Monzon-Bordonaba F, Jimenez-Zamudio L et al. In-vitro secretion of proinflammatory cytokines by human amniochorion carrying hyper-responsive gene polymorphisms of tumour necrosis factor-alpha and interleukin-1beta. Mol Hum Reprod 2000; 9: 625-629.
22. Santtila S, Savinainen K, Hurme M. Presence of the IL-1RA allele 2 (ILRN*2) is associated with enhanced IL-1β production in vitro. Scand J Immunol 1998; 47: 195-198.
23. Danis VA, Millington M, Hyland VJ, Grennan D. Cytokine production by normal human monocytes: Inter-subject variation and relationship to an IL-1 receptor antagonist (IL-1Ra) gene polymorphism. Clin Exp Immunol 1995; 99: 303-310.
24. Buch MH, Bingham SJ, Seto Y et al. Lack of response to Anakinra in rheumatoid arthritis following failure of tumour necrosis factor a blockade. Arthr Rheum 2004; 50: 725-728.
25. Saxne T, Larsson L, Geborek P. Results of anakinra treatment in rheumatoid arthritis patients previously treated with tumour necrosis factor a blockade: Comment on the article by Buch et al. Arthr Rheum 2004; 50: 3049-3051.
26. Schiff MH. Lack of response to anakinra in rheumatoid arthritis following failure of tumour necrosis factor α blockade: Comment on the article by Buch et al. Arthr Rheum 2005; 52: 364-365.
27. Roses AD. Genome-based pharmacogenetics and the pharmaceutical industry. Nat Rev Drug Discov 2002; 1: 541-549.
28. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthr Rheum 1988; 31: 315-324.
29. di Giovine FS, Camp NJ, Cox A et al. Detection and population analysis of IL-1 and TNF gene polymorphisms. In: Balkwill F (ed) Cytokine Molecular Biology. Oxford University Press: Oxford, 2000, pp 21-46.